Two lots of migraine medication have been recalled
Pfizer has volountarily recalled the migraine medication Relpax because of the potential presence of Pseudomonas and Burkholderia.
List view / Grid view
Pfizer has volountarily recalled the migraine medication Relpax because of the potential presence of Pseudomonas and Burkholderia.
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.
The US Federal Trade Commission is investigating whether Johnson and Johnson violated antitrust laws with its medication, Remicade.
The FDA has approved RUXIENCE (rituximab-pvvr), a biosimilar to Rituxan® (rituximab), for treatment of non-Hogkin’s lymphoma and other conditions.
The FDA has announced that it has granted approval to the first nine generic drug applications for Pfizer’s Lyrica treatment.
The global controlled release drug delivery market will be worth an estimated $91.2 billion by 2026, according to a new study.
Vizimpro (dacomitinib) has been recommended as a first-line treatment option for patients with lung cancer.
The price of over 3400 drugs have been hiked in the first half of 2019, surpassing the number of hikes imposed during the same period last year.
Substandard and counterfeit drugs can negatively impact the pharmaceutical industry and patients. Here, we investigate counterfeits in south-east Asia and possible solutions.
Pharmaceutical company, Pfizer, has announced it has completed the acquisition of Therachon for $340 million.
Former FDA Commissioner, Scott Gottlieb, who stepped down from the administration in April, has joined Pfizer’s board of directors.
Pharmaceutical company Pfizer was able to target the distribution of counterfeit Viagra in Hong Kong through serialisation technology.
According to Reuters, GSK has started the sale of some consumer health brands as it seeks to raise £1 billion.
A multi-company system to improve traceability of pharmaceutical products is newly supported by the FDA.
There are many business challenges to developing a biologics drug, one of which is effective data management. In this article, Unjulie Bhanot focuses on efficient data management policies and systems, and how they could improve biologics product development processes.